Castle Biosciences Reports Q2 2026 Revenue of $103.5 Million and Raises Full-Year Guidance
Castle Biosciences (Nasdaq: CSTL) reported second-quarter revenue of $103.5 million for the period ending June 30, 2026, representing a year-over-year increase from $86.2 million in Q2 2025. The company attributed this growth to strong performance across its core diagnostic tests, including DecisionDx®-Melanoma and TissueCypher®, which saw test report volumes rise by 32% compared to the same period last year. Based on this momentum, Castle Biosciences raised its full-year revenue guidance from $345–$355 million to a new range of $365–$375 million. The company also expects positive Adjusted EBITDA for Q3 2026 and the remainder of the year. Despite reporting a net loss of $2.1 million in Q2, driven by non-cash stock-based compensation expenses, Castle Biosciences maintained strong cash flow from operations at $15.2 million. The company highlighted clinical validation for its AdvanceAD-Tx™ test through an independent study showing improved treatment alignment after testing. This reinforces the value of their diagnostic solutions in guiding patient care and supports continued growth.
Tickers: $CSTL